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VETERINARY MICROBIOLOGY
Susceptibility of Clostridium difficile Toward Antimicrobial
Agents Used as Feed Additives for Food Animals
Frank M. Aarestrup1 and Michael Tvede2
A total of 65 toxigenic Clostridium difficile strains isolated from patients with antibiotic-associated diarrhea were
tested for susceptibility to avilamycin, flavomycin, monensin, and salinomycin. Except for flavomycin the
substances showed in vitro efficacy comparable to reports of the currently most commonly used drugs for
treatment of C. difficile. This indicates that these old compounds may be useful for the treatment of C. difficile
infections in man and perhaps for other bacterial causes of diarrhea.
Introduction
C lostridium difficile is an anaerobic spore-formingand often toxin-producing Gram-positive bacterium and
is a major cause of pseudomembraneous colitis and antibi-
otic-associated diarrhea mainly in patients previously ad-
ministrated antimicrobials, as first described by Larson et al.15
and Bartlett et al.6
C. difficile infections have recently increased in incidence
and severity in many regions of North America and many
countries in Europe.13,20 C. difficile is intrinsically resistant to
many antimicrobial agents, and acquired resistance to the
few therapeutically efficient drugs has been rapidly in-
creasing.18 The current treatment regime is associated with
treatment failure in some cases and relapses occur in*20%–
30% of all clinical cases.3 This has increased the interest in
searching for novel and more efficient treatment options and
the development of new antibiotics.5,13
A number of antimicrobial agents, never approved for
human therapy, have for several decades been used for
nontherapeutic purposes or to control coccidia infections in
food animals.1,2 Some of these compounds have shown good
in vitro activity against Clostridium perfringens9,22 and have
been also able to control infections with this bacterium in
poultry19,21 and swine.14 These antimicrobials are included in
the feed and are poorly absorbed in the gut. Thus, we
speculated whether these compounds might have activity
against C. difficile-caused gastrointestinal infections in
humans.
This study was conducted to evaluate the in vitro sus-
ceptibility to avilamycin, flavomycin, monensin, and salino-
mycin against C. difficile isolated from infections in humans




A total of 65 clinical isolates of C. difficile were selected
from cases of antibiotic-associated diarrhea at Rigshospitalet
in Denmark. The isolates were cultured from feces on
cycloserine–cefoxitin–fructose egg yolk agar (Statens Serum
Institute) and identified as C. difficile by usual routine fer-
mentation tests and demonstration of volatile fatty acids by
gas–liquid chromatography according to the manual of the
Virginia Polytechnic Institute.11 Cytotoxin was demonstrated
in a McCoy cell assay established in the laboratory at
Rigshospitalet.12
Antimicrobial susceptibility testing
All isolates were examined for their minimum inhibitory
concentrations (MICs) using twofold dilutions on Brucella
agar supplemented with 5% laked sheep blood (Statens
Serum Institute), 5mg/L hemin (Sigma-Aldrich), and
1mg/L vitamin K (Sigma-Aldrich) according to CLSI stan-
dards.8 Isolates were tested to the following concentrations
of avilamycin (Elanco Animal Health), flavomycin (Hoechst
GmbH), monensin (Elanco Animal Health), and salinomycin
(Huvepharma): 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8, and
16mg/L. Avilamycin and monensin were dissolved in ace-
tone, salinomycin in 99% ethanol, and flavomycin directly in
water before being added to the agar. As quality control
strain, C. difficile ATTC 17857 was included on all agar plates.
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The agar plates were incubated under anaerobic conditions
at 368C for 42–48 hours.
Results
The MICs are shown in Table 1. MIC values for avila-
mycin ranged from 0.03 to 0.25mg/L; two isolates, how-
ever, had MIC values of 2mg/L. MIC values for flavomycin
ranged from 0.25 to 8mg/L, for monensin from 0.03 to
1mg/L, and for salinomycin from 0.03 to 0.5mg/L.
Discussion
Infections caused by C. difficile are increasing in prevalence
and severity. Treatment of these infections is increasingly
difficult because of the development of resistance toward
fluoroquinolones and rifampicin and reduced clinical re-
sponse to metronidazole and vancomycin. The use of vanco-
mycin is further problematic because of the risk of selection for
vancomycin-resistant enterococci and staphylococci.
We tested the in vitro susceptibility of 65 C. difficile isolates
toward avilamycin, flavomycin, monensin, and salinomycin.
All four compounds have been extensively used for decades
in food animals and no toxicological reactions, to our
knowledge, have been ever recorded. Avilamycin, an oligo-
saccharide, and another closely related antimicrobial agent,
everninomicin, were previously under development for
therapeutic use in humans. Avilamycin has been originally
shown to bind to the 30S subunit of ribosome and thereby
interfere with the protein synthesis function.23 Ever-
ninomycin has, however, been shown to bind exclusively to
the 50S subunit.17 In enterococci, resistance to both com-
pounds is mediated by either point mutations in the L16 50S
subunit ribosomal protein4 or a methyltransferase acting on
the 50S subunit.16 Flavomycin is a phosphoglycopeptide that
inhibits peptidoglycan synthesis by inhibiting peptidoglycan
polymerases.7 Several bacterial species exhibit natural resis-
tance to flavomycin, but so far acquired resistance has not
been confirmed.7 Monensin and salinomycin are both iono-
phores and interfere with the natural ion transport system of
both prokaryotic and eukaryotic cells. Staphylococcal and
enterococcal isolates with reduced susceptibility has been
reported,3 but the mechanism has never been elucidated. To
our knowledge, no substances belonging to these classes
have been ever developed for human usage.
All four substances tested had activity against C. difficile;
however, flavomycin had relatively high MIC values,
whereas avilamycin, monensin, and salinomycin had MIC
values comparable to or slightly lower than those reported
for metronidazole and vancomycin.10
These results indicate that some of these old compounds,
which for decades have been used for other purposes, might
find application in human medicine for the treatment of C.
difficile diarrhea and perhaps other chronic diarrhea diseases.
Further studies are, however, necessary to determine the
therapeutic potential and also to explore whether some
negative effects might be associated with a future use of one
or more of these compounds in human medicine.
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